All In Biotech

Drug Trial Radar · NCT02394483

Single Ascending Oral Dose Study of F901318

F901318 - A Phase I, Double-Blind, Placebo Controlled, Single Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: Sep 19, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Oct 2015

Primary completion

Sep 2016

Study completion Sep 2016

Sponsor

Lead sponsor
F2G LtdIndustry
Sponsor type
Industry
Collaborators
Simbec-Orion Group
First posted
Mar 20, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Double blind, placebo controlled, ascending single oral dose, sequential group study. Forty subjects will complete the study in 5 cohorts (Groups A to E), each group consisting of 8 subjects. Each subject will be on study for approximately 6 weeks. Each subject will participate in one treatment cohort only, residing at the Clinical Research Unit (CRU) from Day -1 (the day before dosing) to Day 6 (120 hours post-dose). Each cohort will be dosed in a leading edge design in which two subjects will receive study drug (1 active and 1 placebo) on the first dosing day, and the last 6 will receive study drug (5 active and 1 placebo) on the second dosing day. All subjects will return for a post-study visit 8 to 10 days after the dose of study medication. Cohorts will be dosed at 2 weekly intervals. There will be a review of safety data, after the first two subjects have been dosed and before dosing of the subsequent six subjects. There will be a complete review of safety and pharmacokinetic data of each cohort prior to each dose escalation.

Conditions

  • Invasive Aspergillosis

Interventions

  • F901318 safetyDrug

    Safety assessments

  • F901318 tolerabilityDrug

    Tolerability assessments

  • F901318 pharmacokineticsDrug

    Pharmacokinetic assessments

  • Placebo safetyOther

    Safety assessments

  • Placebo tolerabilityOther

    Placebo tolerability

  • Placebo pharmacokineticsOther

    Plaacebo pharmacokinetics

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety (Adverse events)Time frame: 10 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Simbec Orion

    Merthyr Tydfil, Wales, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.